European Leukemia Trial Registry
Trial: AMLCG 2008

More Details
Title Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in AML
Scientific Title A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia
Short Title AMLCG 2008
Trialgroup AML-CG
Type of Trial multicentric, randomized, prospective, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Follow up
Start of Recruitment 04.01.2010
Leader Hiddemann, Prof. Dr. med., Wolfgang
Contactperson

Study coordinator
Braess, Prof. Dr. med., Jan
Tel: +49 (0)941 369 2153
Fax: +49 (0)941 369 2165
Email: jan.braess@barmherzige-regensburg.de

Data-Manager
Unterhalt, Dr., Michael
Tel: +49 (0)89 7095-4915
Fax: +49 (0)89 7095-7900

randomisation
Burgard, Elke
Tel: +49 (0)251 83-55272
Fax: +49 (0)251 83-55277
Email: burgard@mednet.uni-muenster.de

Centre of Trial Klinikum der Ludwig-Maximilians-Universität München
Shortprotocol Shortprotocol
Diagnostics

Central diagnostics
Labor für spezielle Leukämiediagnostik, Universität München
Immunologisches Markerlabor der Charité Berlin, Campus Benjamin-Franklin

created 12.01.2010 Irene Gleske
changed 06.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org